Shenzhen Salubris Pharmaceuticals Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
4,087
- Stock Symbol
-
002294
- Investments
-
20
- Share Price
-
$3.95
- (As of Thursday Closing)
Shenzhen Salubris Pharmaceuticals General Information
Description
Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalosporins, and bone resorption inhibitors. Its products mainly focus on the areas of cardio-cerebral vascular disease, diabetes, complications, anti-tumor, and orthopedics. Its business lines include high-end chemical drugs, biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other countries and regions.
Contact Information
Website
www.salubris.comCorporate Office
- 37th Floor, Block B, NEO Greenview Plaza
- Number 6009 Shennan Avenue, Futian District
- Shenzhen, Guangdong
- China
Corporate Office
- 37th Floor, Block B, NEO Greenview Plaza
- Number 6009 Shennan Avenue, Futian District
- Shenzhen, Guangdong
- China
Shenzhen Salubris Pharmaceuticals Stock Performance
As of 19-Nov-2026, Shenzhen Salubris Pharmaceuticals’s stock price is $3.95. Its current market cap is $4.41B with 1.11B shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.95 | $4.02 | $3.88 - $10.33 | $4.41B | 1.11B | 12M | $0.09 |
Shenzhen Salubris Pharmaceuticals Financials Summary
As of 30-Sep-2026, Shenzhen Salubris Pharmaceuticals has a trailing 12-month revenue of $704M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 5,027,095 | 7,732,738 | 4,507,137 | 4,876,058 |
| Revenue | 704,245 | 605,266 | 559,160 | 475,675 |
| EBITDA | 99,355 | 144,991 | 136,278 | 132,312 |
| Net Income | 103,733 | 90,596 | 83,837 | 81,990 |
| Total Assets | 1,675,569 | 1,614,733 | 1,433,625 | 1,325,603 |
| Total Debt | 143,961 | 100,913 | 18,339 | 8,953 |
Shenzhen Salubris Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Shenzhen Salubris Pharmaceuticals Patents
Shenzhen Salubris Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026228703-A1 | Α4β7 integrin compound, and preparation method therefor and use thereof | Pending | 30-Apr-2025 | ||
| WO-2026228618-A1 | Amylin receptor agonist, and preparation method therefor and use thereof | Pending | 28-Apr-2025 | ||
| WO-2026228543-A1 | Recombinant fusion protein having multiple activities and use thereof | Pending | 27-Apr-2025 | ||
| WO-2026223737-A1 | Bicyclic substituted compound and use thereof in apj receptor-related diseases | Pending | 24-Apr-2025 | ||
| WO-2026219222-A1 | Pcsk9 and lpa dual-targeting compound and use thereof | Pending | 16-Apr-2025 |
Shenzhen Salubris Pharmaceuticals Signals
Shenzhen Salubris Pharmaceuticals Investments & Acquisitions (20)
Shenzhen Salubris Pharmaceuticals’s most recent deal was a Later Stage VC with Precision Scientific (China) for . The deal was made on 09-Dec-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Precision Scientific (China) | 09-Dec-2025 | Later Stage VC | Laboratory Services (Healthcare) | ||
| Precision Scientific (China) | 25-Nov-2024 | Later Stage VC | Laboratory Services (Healthcare) | ||
| Precision Scientific (China) | 21-Feb-2024 | Later Stage VC | Laboratory Services (Healthcare) | ||
| Precision Scientific (China) | 25-Jun-2023 | Later Stage VC | Laboratory Services (Healthcare) | ||
| Adicon Clinical Laboratory | 19-Jun-2023 | IPO | Laboratory Services (Healthcare) |
Shenzhen Salubris Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
39.23 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Shenzhen Salubris Pharmaceuticals Exits (3)
Shenzhen Salubris Pharmaceuticals’s most recent exit was on 12-Feb-2019 from Viracta Therapeutics. The exit was categorized as with 5 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Viracta Therapeutics | 12-Feb-2019 | Completed |
|
||
| MedAlliance (Drug Delivery) | 21-May-2018 | Completed |
|
||
| Go Therapeutics | 08-Aug-2017 | Early Stage VC | Completed |
Shenzhen Salubris Pharmaceuticals Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Salubris Biomedical Engineering | Shenzhen, China | 2009 | |
| Jinkai Biotechnology | Chengdu, China | 2008 |
Shenzhen Salubris Pharmaceuticals FAQs
-
When was Shenzhen Salubris Pharmaceuticals founded?
Shenzhen Salubris Pharmaceuticals was founded in 1998.
-
Where is Shenzhen Salubris Pharmaceuticals headquartered?
Shenzhen Salubris Pharmaceuticals is headquartered in Shenzhen, China.
-
What is the size of Shenzhen Salubris Pharmaceuticals?
Shenzhen Salubris Pharmaceuticals has 4,087 total employees.
-
What industry is Shenzhen Salubris Pharmaceuticals in?
Shenzhen Salubris Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Shenzhen Salubris Pharmaceuticals a private or public company?
Shenzhen Salubris Pharmaceuticals is a Public company.
-
What is Shenzhen Salubris Pharmaceuticals’s stock symbol?
The ticker symbol for Shenzhen Salubris Pharmaceuticals is 002294.
-
What is the current stock price of Shenzhen Salubris Pharmaceuticals?
As of 19-Nov-2026 the stock price of Shenzhen Salubris Pharmaceuticals is $3.95.
-
What is the current market cap of Shenzhen Salubris Pharmaceuticals?
The current market capitalization of Shenzhen Salubris Pharmaceuticals is $4.41B.
-
What is Shenzhen Salubris Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Shenzhen Salubris Pharmaceuticals is $704M.
-
What is Shenzhen Salubris Pharmaceuticals’s annual earnings per share (EPS)?
Shenzhen Salubris Pharmaceuticals’s EPS for 12 months was $0.09.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process